Cara Corp (TVRD): רווח נקי למניה (EPS TTM)

TVRD (Cara Therapeutics Inc) - סמל מסחרי של החברה

The growth of Cara Therapeutics Inc (TVRD) is based on the expansion of the drug Korsuva within the nephrology segment. Net income per share over the last 12 months confirms this resilience, where -2.70 describes the current status of the metric. Development has been bolstered by the automation of substance synthesis, while batch production has been entrusted to certified contract centers, optimizing the company's operating expenses.

TVRD רווח למניה ב-12 החודשים האחרונים Cara Corp (04.07.2022 - 18.11.2026)

פילוחים אנליטיים ודוחות נתונים של חברת Cara Pharma (TVRD)

ניתוח ראשוני של החברה:caratherapeutics.com (TVRD)
סחורת הדגל של Cara Therapeutics, Inc.

This indicator reflects overall business efficiency by comparing net income with the total number of securities to determine the actual profit share per asset. For Cara Therapeutics Inc (TVRD), the automation of molecular target bioscreening should optimize operating expenses, which will directly impact the annual net income per share trend, allowing investors to promptly identify any hidden weakening of the issuer's fundamental position.